Global Brand Drugs Market Professional Survey Report 2019
- 1.4.1 Research Process
- 1.4.2 Data Triangulation
- 1.4.3 Research Approach
- 1.4.4 Base Year
- 1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
- 1.5.2 Covid-19 Impact: Commodity Prices Indices
- 1.5.3 Covid-19 Impact: Global Major Government Policy
2 Global Brand Drugs Quarterly Market Size Analysis
- 2.1 Brand Drugs Business Impact Assessment - COVID-19
- 2.1.1 Global Brand Drugs Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
- 2.1.2 Global Brand Drugs Price, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
- 2.2 Global Brand Drugs Quarterly Market Size 2020-2021
- 2.3 COVID-19-Driven Market Dynamics and Factor Analysis
- 2.3.1 Drivers
- 2.3.2 Restraints
- 2.3.3 Opportunities
- 2.3.4 Challenges
3 Quarterly Competitive Assessment, 2020
- 3.1 Global Brand Drugs Quarterly Market Size by Manufacturers, 2019 VS 2020
- 3.2 Global Brand Drugs Factory Price by Manufacturers
- 3.3 Location of Key Manufacturers Brand Drugs Manufacturing Factories and Area Served
- 3.4 Date of Key Manufacturers Enter into Brand Drugs Market
- 3.5 Key Manufacturers Brand Drugs Product Offered
- 3.6 Mergers & Acquisitions, Expansion Plans
4 Impact of Covid-19 on Brand Drugs Segments, By Type
- 4.1 Introduction
- 1.4.1 Biopharmaceutical
- 1.4.2 Chemistry Medicine
- 4.2 By Type, Global Brand Drugs Market Size, 2019-2021
- 4.2.1 By Type, Global Brand Drugs Market Size by Type, 2020-2021
- 4.2.2 By Type, Global Brand Drugs Price, 2020-2021
5 Impact of Covid-19 on Brand Drugs Segments, By Application
- 5.1 Overview
- 5.5.1 Hospital
- 5.5.2 Clinic
- 5.5.3 Other
- 5.2 By Application, Global Brand Drugs Market Size, 2019-2021
- 5.2.1 By Application, Global Brand Drugs Market Size by Application, 2019-2021
- 5.2.2 By Application, Global Brand Drugs Price, 2020-2021
6 Geographic Analysis
- 6.1 Introduction
- 6.2 North America
- 6.2.1 Macroeconomic Indicators of US
- 6.2.2 US
- 6.2.3 Canada
- 6.3 Europe
- 6.3.1 Macroeconomic Indicators of Europe
- 6.3.2 Germany
- 6.3.3 France
- 6.3.4 UK
- 6.3.5 Italy
- 6.4 Asia-Pacific
- 6.4.1 Macroeconomic Indicators of Asia-Pacific
- 6.4.2 China
- 6.4.3 Japan
- 6.4.4 South Korea
- 6.4.5 India
- 6.4.6 ASEAN
- 6.5 Rest of World
- 6.5.1 Latin America
- 6.5.2 Middle East and Africa
7 Company Profiles
- 7.1 Pfizer
- 7.1.1 Pfizer Business Overview
- 7.1.2 Pfizer Brand Drugs Quarterly Production and Revenue, 2020
- 7.1.3 Pfizer Brand Drugs Product Introduction
- 7.1.4 Pfizer Response to COVID-19 and Related Developments
- 7.2 Roche
- 7.2.1 Roche Business Overview
- 7.2.2 Roche Brand Drugs Quarterly Production and Revenue, 2020
- 7.2.3 Roche Brand Drugs Product Introduction
- 7.2.4 Roche Response to COVID-19 and Related Developments
- 7.3 Sanofi
- 7.3.1 Sanofi Business Overview
- 7.3.2 Sanofi Brand Drugs Quarterly Production and Revenue, 2020
- 7.3.3 Sanofi Brand Drugs Product Introduction
- 7.3.4 Sanofi Response to COVID-19 and Related Developments
- 7.4 Johnson & Johnson
- 7.4.1 Johnson & Johnson Business Overview
- 7.4.2 Johnson & Johnson Brand Drugs Quarterly Production and Revenue, 2020
- 7.4.3 Johnson & Johnson Brand Drugs Product Introduction
- 7.4.4 Johnson & Johnson Response to COVID-19 and Related Developments
- 7.5 Merck & Co. (MSD)
- 7.5.1 Merck & Co. (MSD) Business Overview
- 7.5.2 Merck & Co. (MSD) Brand Drugs Quarterly Production and Revenue, 2020
- 7.5.3 Merck & Co. (MSD) Brand Drugs Product Introduction
- 7.5.4 Merck & Co. (MSD) Response to COVID-19 and Related Developments
- 7.6 Novartis
- 7.6.1 Novartis Business Overview
- 7.6.2 Novartis Brand Drugs Quarterly Production and Revenue, 2020
- 7.6.3 Novartis Brand Drugs Product Introduction
- 7.6.4 Novartis Response to COVID-19 and Related Developments
- 7.7 AbbVie
- 7.7.1 AbbVie Business Overview
- 7.7.2 AbbVie Brand Drugs Quarterly Production and Revenue, 2020
- 7.7.3 AbbVie Brand Drugs Product Introduction
- 7.7.4 AbbVie Response to COVID-19 and Related Developments
- 7.8 Gilead Sciences
- 7.8.1 Gilead Sciences Business Overview
- 7.8.2 Gilead Sciences Brand Drugs Quarterly Production and Revenue, 2020
- 7.8.3 Gilead Sciences Brand Drugs Product Introduction
- 7.8.4 Gilead Sciences Response to COVID-19 and Related Developments
- 7.9 GlaxoSmithKline (GSK)
- 7.9.1 GlaxoSmithKline (GSK) Business Overview
- 7.9.2 GlaxoSmithKline (GSK) Brand Drugs Quarterly Production and Revenue, 2020
- 7.9.3 GlaxoSmithKline (GSK) Brand Drugs Product Introduction
- 7.9.4 GlaxoSmithKline (GSK) Response to COVID-19 and Related Developments
- 7.10 Amgen
- 7.10.1 Amgen Business Overview
- 7.10.2 Amgen Brand Drugs Quarterly Production and Revenue, 2020
- 7.10.3 Amgen Brand Drugs Product Introduction
- 7.10.4 Amgen Response to COVID-19 and Related Developments
- 7.11 AstraZeneca
- 7.11.1 AstraZeneca Business Overview
- 7.11.2 AstraZeneca Brand Drugs Quarterly Production and Revenue, 2020
- 7.11.3 AstraZeneca Brand Drugs Product Introduction
- 7.11.4 AstraZeneca Response to COVID-19 and Related Developments
- 7.12 Bristol-Myers Squibb
- 7.12.1 Bristol-Myers Squibb Business Overview
- 7.12.2 Bristol-Myers Squibb Brand Drugs Quarterly Production and Revenue, 2020
- 7.12.3 Bristol-Myers Squibb Brand Drugs Product Introduction
- 7.12.4 Bristol-Myers Squibb Response to COVID-19 and Related Developments
- 7.13 Eli Lilly
- 7.13.1 Eli Lilly Business Overview
- 7.13.2 Eli Lilly Brand Drugs Quarterly Production and Revenue, 2020
- 7.13.3 Eli Lilly Brand Drugs Product Introduction
- 7.13.4 Eli Lilly Response to COVID-19 and Related Developments
- 7.14 Teva
- 7.14.1 Teva Business Overview
- 7.14.2 Teva Brand Drugs Quarterly Production and Revenue, 2020
- 7.14.3 Teva Brand Drugs Product Introduction
- 7.14.4 Teva Response to COVID-19 and Related Developments
- 7.15 Bayer
- 7.15.1 Bayer Business Overview
- 7.15.2 Bayer Brand Drugs Quarterly Production and Revenue, 2020
- 7.15.3 Bayer Brand Drugs Product Introduction
- 7.15.4 Bayer Response to COVID-19 and Related Developments
- 7.16 Novo Nordisk
- 7.16.1 Novo Nordisk Business Overview
- 7.16.2 Novo Nordisk Brand Drugs Quarterly Production and Revenue, 2020
- 7.16.3 Novo Nordisk Brand Drugs Product Introduction
- 7.16.4 Novo Nordisk Response to COVID-19 and Related Developments
- 7.17 Allergan
- 7.17.1 Allergan Business Overview
- 7.17.2 Allergan Brand Drugs Quarterly Production and Revenue, 2020
- 7.17.3 Allergan Brand Drugs Product Introduction
- 7.17.4 Allergan Response to COVID-19 and Related Developments
- 7.18 Takeda
- 7.18.1 Takeda Business Overview
- 7.18.2 Takeda Brand Drugs Quarterly Production and Revenue, 2020
- 7.18.3 Takeda Brand Drugs Product Introduction
- 7.18.4 Takeda Response to COVID-19 and Related Developments
- 7.19 Boehringer Ingelheim
- 7.19.1 Boehringer Ingelheim Business Overview
- 7.19.2 Boehringer Ingelheim Brand Drugs Quarterly Production and Revenue, 2020
- 7.19.3 Boehringer Ingelheim Brand Drugs Product Introduction
- 7.19.4 Boehringer Ingelheim Response to COVID-19 and Related Developments
- 7.20 Takeda
- 7.20.1 Takeda Business Overview
- 7.20.2 Takeda Brand Drugs Quarterly Production and Revenue, 2020
- 7.20.3 Takeda Brand Drugs Product Introduction
- 7.20.4 Takeda Response to COVID-19 and Related Developments
8 Supply Chain and Sales Channels Analysis
- 8.1 Brand Drugs Supply Chain Analysis
- 8.1.1 Brand Drugs Supply Chain Analysis
- 8.1.2 Covid-19 Impact on Brand Drugs Supply Chain
- 8.2 Distribution Channels Analysis
- 8.2.1 Brand Drugs Distribution Channels
- 8.2.2 Covid-19 Impact on Brand Drugs Distribution Channels
- 8.2.3 Brand Drugs Distributors
- 8.3 Brand Drugs Customers
9 Key Findings
10 Appendix
- 10.1 About Us
This report covers market size and forecasts of Brand Drugs, including the following market information:
Global Brand Drugs Market Size, 2019-2021, and 2020 (quarterly data), (US$ Million) & (K Units)
Global Brand Drugs Market Size by Type and by Application, 2019-2021, and 2020 (quarterly data), (US$ Million) & (K Units)
Global Brand Drugs Market Size by Region (and Key Countries), 2019-2021, and 2020 (quarterly data), (US$ Million) & (K Units)
Global Brand Drugs Market Size by Company, 2019- 2020 (quarterly data), (US$ Million) & (K Units)
Key market players
Major competitors identified in this market include Pfizer, Roche, Sanofi, Johnson & Johnson, Merck & Co. (MSD), Novartis, AbbVie, Gilead Sciences, GlaxoSmithKline (GSK), Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Teva, Bayer, Novo Nordisk, Allergan, Takeda, Boehringer Ingelheim, Takeda, etc.
Based on the Region:
Asia-Pacific (China, Japan, South Korea, India and ASEAN)
North America (US and Canada)
Europe (Germany, France, UK and Italy)
Rest of World (Latin America, Middle East & Africa)
Based on the Type:
Biopharmaceutical
Chemistry Medicine
Based on the Application:
Hospital
Clinic
Other